ACE2 and COVID-19: This controversy arises because ACEIs/ARBs have several mechanisms whereby they can influence COVID-19 outcomes, in some cases with contrary effects: (i) on the one hand, they could increase the risk of COVID-19 outcomes, since in the medium term inhibition of ACE2 (angiotensin-converting enzyme 2) would bring about an increase in its receptors (Alhaddad et al. 2022; Asiimwe et al. 2022Udhaya et al., 2021), and this, on being the COVID-19 gateway, would in turn increase susceptibility to the virus (Gómez et al. 2020; Möhlendick et al. 2021).